Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Keil

Showing results (31-40 of 82) with videos related to

Pageof 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 19, 2016
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14)Michael A Fridrik, Ulrich Jaeger, Andreas Petzer, et al.
Journal of Personalized Medicine|August 26, 2022
Wnt/β-Catenin-Pathway Alterations and Homologous Recombination Deficiency in Cholangiocarcinoma Cell Lines and Clinical Samples: Towards Specific VulnerabilitiesAlexander Scheiter, Frederik Hierl, Ingrid Winkel, et al.
Leukemia & Lymphoma|September 14, 2004
Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantationHermine Agis, Christine Mannhalter, Wolfgang R Sperr, et al.
Wiener Klinische Wochenschrift|October 9, 2003
Efficacy and tolerability of non-invasive ventilation delivered via a newly developed helmet in immunosuppressed patients with acute respiratory failureWerner Rabitsch, Peter Schellongowski, Wolfgang J Köstler, et al.
Cells|January 8, 2023
Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph<sup>+</sup> Chronic Myeloid LeukemiaIrina Sadovnik, Daniel Ivanov, Dubravka Smiljkovic, et al.
Current Oncology (Toronto, Ont.)|April 3, 2021
Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for TherapyAlexander Scheiter, Felix Keil, Florian Lüke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2010
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II studyHeinz Ludwig, Zdenek Adam, Roman Hajek, et al.
Wiener Klinische Wochenschrift|February 21, 2006
Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicityNina Worel, Axel Schulenburg, Margit Mitterbauer, et al.
Transfusion|July 19, 2003
ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantationNina Worel, Peter Kalhs, Felix Keil, et al.
European Journal of Haematology|December 16, 2019
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomasSandro M Wagner, Thomas Melchardt, Alexander Egle, et al.
Pageof 9

Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
European Journal of Cancer (Oxford, England : 1990)|March 19, 2016
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14)Michael A Fridrik, Ulrich Jaeger, Andreas Petzer, et al.
Journal of Personalized Medicine|August 26, 2022
Wnt/β-Catenin-Pathway Alterations and Homologous Recombination Deficiency in Cholangiocarcinoma Cell Lines and Clinical Samples: Towards Specific VulnerabilitiesAlexander Scheiter, Frederik Hierl, Ingrid Winkel, et al.
Leukemia & Lymphoma|September 14, 2004
Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantationHermine Agis, Christine Mannhalter, Wolfgang R Sperr, et al.
Wiener Klinische Wochenschrift|October 9, 2003
Efficacy and tolerability of non-invasive ventilation delivered via a newly developed helmet in immunosuppressed patients with acute respiratory failureWerner Rabitsch, Peter Schellongowski, Wolfgang J Köstler, et al.
Cells|January 8, 2023
Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph<sup>+</sup> Chronic Myeloid LeukemiaIrina Sadovnik, Daniel Ivanov, Dubravka Smiljkovic, et al.
Current Oncology (Toronto, Ont.)|April 3, 2021
Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for TherapyAlexander Scheiter, Felix Keil, Florian Lüke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2010
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II studyHeinz Ludwig, Zdenek Adam, Roman Hajek, et al.
Wiener Klinische Wochenschrift|February 21, 2006
Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicityNina Worel, Axel Schulenburg, Margit Mitterbauer, et al.
Transfusion|July 19, 2003
ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantationNina Worel, Peter Kalhs, Felix Keil, et al.
European Journal of Haematology|December 16, 2019
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomasSandro M Wagner, Thomas Melchardt, Alexander Egle, et al.
Pageof 9